Radetec Diagnostics develops fast COVID19 test

With assistance from the Additive Manufacturing Hub at AMTIL, MedTech Actuator startup Radetec Diagnostics has developed an innovative device to facilitate fast and inexpensive testing of various infectious diseases – including COVID19.

Melbourne-based Radetec Diagnostics is a bio-nanotechnology company dedicated to developing a world-leading “platform technology” based on quantum dots – advanced luminescent nanoparticles that can be used as labels for imaging and sensing applications.

This has a wide range of clinical applications, particularly in the field of point-of-care rapid diagnostics, portable in-vitro diagnostic (IVDs) devices that are used for fast and inexpensive testing of various infectious diseases such as COVID19, sexually transmitted infections (STIs) or even cancer and Parkinson’s disease biomarkers.

The Additive Manufacturing Hub recently supported Radetec in developing the reader just in time for the roll-out of its first product – a COVID19 antigen point-of-care rapid test. The support allowed for a timely delivery of the entire set of diagnostics devices (reader and test strip) to US-based distribution partners for immediate live trial and evaluation.

Read more about Radetec’s game-changing technology in this recent case study from the Additive Manufacturing Hub.

Radetec has now opened equity financing to accelerate the execution of their go-to-market strategy.

The company is now:

  • revenue positive – through ancillary product sales
  • trialling their COVID19 point-of-care test in Indian hospitals, with regulatory approval underway
  • trialling their COVID19 point-of-care test in US hospitals, and working closely with a US distributor
  • developing a chlamydia point-of-care test – with the prototype ready by the end of 2021
  • building a product pipeline – with a suite of products at various stages of development.

To express interest in becoming a Radetec Diagnostics investor, reach out to Lee Xie – Radetec Commercial Director at l.xie[@]radetecdiagnostics.com.

Founders powering the next wave of health innovation.

Congratulations to founders on recently completing MedTech Actuator – Asia Pacific’s MedTech catalyst.

We are proud to support our fifth cohort in radically accelerating their medical, health or biological technology prototype or proof-of-concept to improve and save lives.

Thank you so much to every founder for being a part of the industry-led MedTech Actuator. We are delighted to have you on board in the MedTech Actuator™ innovation ecosystem for life and can’t wait to see where your journey takes you next.

Congratulations to our new MedTech Actuator alumni

Congratulations to all cohort five founders and teams including:

  • Beta Medtech – Edison Bellarmin, Thomas Ooi | Smart patch for the detection and monitoring of pressure ulcers.
  • ChezLeon – Cheryl Pollock | Passive massage wear for treatment of lymphoedema as a side effect of cancer treatment.
  • CPAP Buddy by Tasmanian Medical Innovations – Kathleen Lim, Lachlann McLeod, Cameron Keating, Peter Dargaville, Andrew Marshall | A continuous monitoring system that makes breathing support safer for preterm infants.
  • Diag-Nose Medical – Eldin Rostom, David Yen, Brian Wang, Josie Xu | Non-invasive diagnostics for better rhinology treatments.
  • EloCare – Mabel Nguyen, Fandi Peng | Innovating in the internet of medical things and AI technology to help people live longer and age gracefully.
  • Gabriel – Maria Crews, Nick Crews | Making it possible for seniors to live better for longer.
  • HiCura Medical – Cailin Ng, Yusong Leng | AI technology reducing risks and discomfort for patients during childbirth.
  • Medicsen | Needle-free smart patch for painless drug delivery.
  • Onward Health Research – Martin Lim | A digital health platform enabling world-class clinical research in emerging markets.
  • PhysiPal – Aaya Hakeem, Ahmed Hakeem | A device and app combination that allows patients to take charge of their physiotherapy rehabilitation at home.
  • Recovery App – Allan Molloy, Myles Coolican, Tony Nicol | Digital health platform to optimise outcomes and reduce costs associated with major orthopaedic surgery.
  • Repli-med – Zoe Keon-Cohen, Thomas Sutton | 3D printed models to train and help prepare surgeons and anaesthetists for eye and spine procedures.
  • TuCann – Maryam Soomro, Kenneth Wong, Santiago Beltran Diaz | Cannula solution, simplifying the cannulation process and decreasing likelihood of infection

Where to from here?

Founders can now tap into MedTech Actuator’s unrivalled network – including 85 partners and 75 mentors from some of the largest names in health innovation spanning multi-national corporations, hospitals and clinicians, investor groups and VCs, professional service partners, universities and research institutions, and product development firms.

They join an alumni network of the brightest emerging startups from across Asia Pacific, and our networks are their networks as they scale up, prepare for exit and beyond.

About MedTech Actuator

The MedTech Actuator’s specialised acceleration model surrounds startups with the ecosystem support they need to bring their MedTech, HealthTech or BioTech innovation to the patients and clinicians who need it most.

Through MedTech Actuator’s intensive mentorship, industry collaboration, up to AUD$200K initial capital injection and capital raising support, the founders can achieve in 15 months what can typically take 3 years or more.

Embedded in the MedTech Actuator™ ecosystem, founders radically advance their technology development, raise seed capital, and build critical business and management skills. They become primed and ready to grow their venture even further – including raising series A funding, commencing clinical trials, gaining regulatory approvals, and moving to at-scale manufacturing, and market launch.

More on MedTech Actuator, or subscribe below for news on upcoming intakes.

EloCare: Helping people age gracefully with IoMT technology.

MedTech Actuator startup EloCare Pte Ltd is innovating in the internet of medical things (IoMT) and artificial intelligence (AI) to develop connected and smart healthcare devices that help people live longer and age gracefully.

Dr Mabel Yen Ngoc Nguyen and Fandi Peng founded Singapore-based EloCare, bringing their strong medical research, engineering, and entrepreneurial backgrounds to the company – with a focus on chronic and aging care.

Mabel and Fandi discovered that there was no reliable tool to detect and monitor over 35 menopausal symptoms, and went on to build the first menopause tracker. The wearable and accompanying mobile app can serve as a personalised healthcare assistant to help women make more informed decisions, with the support of their physician, about how to manage menopause. Easy to use and secure, the solution monitors symptoms through biomarkers and self-assessments, and interprets this data to provide lifestyle and medical suggestions. The team is working closely with researchers and clinicians to develop this solution.

“Throughout the R&D process, we uncovered more healthcare problems in aging and chronic care that can be addressed with our IoMT infrastructure. We are now working with our clinical partners to deliver better care,” says Mabel, EloCare CEO and Co-Founder.

EloCare recently won the Open Innovation Challenge 2020 for Industry Track, delivered by Enterprise Singapore in partnership with five of Singapore’s leading healthcare providers. The award opens more opportunities for EloCare to co-develop, test, and deploy solutions using their IoMT infrastructure with healthcare providers.


MedTech Actuator x Elocare

Starting with an idea, preliminary research, and a raw prototype the team joined Asia Pacific’s MedTech catalyst MedTech Actuator in 2020 to develop their prototype and go-to-market, IP, and regulatory strategies – and to connect with industry experts and potential investors.

“The MedTech Actuator has a strong local and international support network that spans government, product development, corporate, clinical, research, investor, and VC partners,” says Mabel.

Being embedded in this ecosystem gave EloCare brand advantages and opportunities to connect with strategic partners and investors. The MedTech Actuator has helped EloCare to connect with the right individuals for feedback and advice in the health innovation ecosystem, and the founding team would not hesitate to recommend the program to emerging founders.

“Navigating a startup in the MedTech space has unique challenges with a longer time horizon compared to a typical startup. Being in the right network and getting professional support early from MedTech Actuator can help startups avoid costly lessons down the road and tap into many opportunities to connect with strategic partners and investors.”

Mabel says the team was fortunate to have Johannes Mang as a mentor to guide them during the program and refine company strategies.

“Johannes is very experienced in the different stages of a startup journey and willing to put himself in our shoes to work through problems and share his insights,” says Mabel.

Photo of road at dusk, pink sky, street lights, empty road in one lane, car light streak through lane travelling opposite direction.

EloCare tips for early-stage MedTech entrepreneurs

Mabel notes that early-stage startups share a common challenge to develop a clear vision of what can be achieved in the short-term and long-term.

“Founders can be ambitious in their startup vision to create a disruptive solution. However being an early-stage startup with time and resource constraints, it is important to have a balance of ambition and pragmatism and to be flexible with goals,” says Mabel.

Mabel recommends ensuring the long-term vision can be broken down into attainable and profitable milestones. She says that it is also important to maintain focus and ambition – always working towards creating impact and developing a competitive advantage.

“Within the EloCare team, we as founders have intense discussions about our mission and plans for the company every time that we assess our progress and challenges. While it is not an easy discussion, it is essential for the life and growth of the company,” says Mabel.

Mabel believes that founders and early team members need to remain resilient and passionate to overcome constant uncertainties and challenges in building a startup.

“Most people will tell you why an idea doesn’t work, and most of the time, they are right. But it is more important to think about how to make something work,” says Mabel.

“Be open-minded enough to accept if a solution or an idea doesn’t work in the end – but only after putting 100% effort into trying to make it work first. On another note, make sure you ask for feedback from the right audience!”

Learn more about EloCare.

Photos by Anton Maksimov juvnsky and Jack B on Unsplash

Our village is raising MedTech’s next wave of innovators.

Thank you to health innovation experts from across Asia Pacific and the US who recently shared their industry insights and knowledge through MedTech Actuator sprints with the region’s best emerging health entrepreneurs.

As Asia Pacific’s MedTech catalyst, MedTech Actuator is a 15-month, industry-led, venture-backed program that aggressively funds and accelerates medical, health and biological technology startups. Our latest MedTech Actuator cohort is driving innovation for patients and clinicians who need it most, in diverse fields spanning IVF, prosthetics, rehabilitation and more.

The sprints: relentless execution towards market success.

Through our recent MedTech Actuator sprints, founders developed expertise in business models, pitching, customer validation, IP, regulations, reimbursement, clinical trials in Australia, Singapore, the US, and the EU.

This expertise will be crucial to their success in determining a pathway to market, including how long it will take to secure their first paying customer.

With these important foundations in place MedTech Actuator startups are now working to address critical risk areas, before ramping up commercialisation activities.

Our village, helping to take founders there.

It takes a village to raise a startup and health innovation is no exception. These latest MedTech Actuator sprints would not have been possible without the support of our village.

Our sincere thanks to all the people and companies that have contributed to our latest cohort so far:

  • Alex Newton – NAVI
  • Tony Sinclair – Impactor
  • Gemma and Lucas Testro – SONDO
  • Matt Godden – Australian Healthcare Solutions
  • Nairy Baghdikian – Cogentum
  • Penelope Lane – SCALE
  • Michelle Gallaher – Opyl
  • Stefaan Van Der Meulen – Syntactx
  • Nick Opie – Synchron
  • Jean-Nicolas Boudaud – Brandwood
  • Marco Kalms – Kalms Consulting
  • Tom Hughes – LabCorp
  • Lee Phin Peng, Hee Choon – Singapore Biodesign
  • Amrish Nair – Biorithm
  • Jason Lim, Yang Jie Tan – Stendard
  • Lawrence Ho and Rina Lim – NUHS
  • Cher Hwa Teo, Ee Lim, Michael Ho – NHIC Singapore
  • Tan Cher Heng – NHG

Our village spans far and wide across the globe. We also extend our sincere thanks to MedTech Actuator partners for their generous contribution.

  • Jarred Roache – Roache Design
  • Matthew Gould, Leah Han, Dr Anna Bellamy-McIntyre, Matt Cary, Joseph Barker – EY
  • Rachel Hooke, Eddie Walker – FB Rice
  • Jonathan Kelp, Simone Mitchell & Kristi Geddes – Minter Ellison
  • Natalie Lawandi, Rashmi Joglekar – MedTronic
  • Dr Megan Robertson – St Vincent’s
  • Chris Rupp, Stefaan van der Meulen – NAMSA
  • Frank Jaskulke – Medical Alley
  • Anh Bourcet – J&J Singapore
  • Johanes Candra, Sherilyn Chan – EY Singapore
  • Delon Toh – ESG

We are grateful for everyone’s time, drive, energy, and enthusiasm – we could not do this without you and are excited to support the continued growth of our founders.

Find out more about MedTech Actuator.

MedTech Actuator Origin is back – apply today!

Are you an aspiring entrepreneur with a MedTech, BioTech or HealthTech startup idea? Apply now for the 2021 MedTech Actuator Origin!

All superheroes have a beginning and so do startup founders. Transform your idea or research with MedTech Actuator Origin – a two month early-stage entrepreneurship competition that will help you translate your concept into an impact orientated health venture.

Whether you’re a researcher, scientist, clinician, student or garage inventor, MedTech Actuator Origin is looking for passionate entrepreneurs to transform healthcare. Apply today!

The MedTech Actuator Origin experience

Delivered in-person and online, MedTech Actuator Origin is open to Australian health entrepreneurs and will run from October to December 2021. Our experts will pressure test your idea and expose you to the world of startups through:

  • Workshops – gain insight into what it takes to protect your idea and learn how to craft a prize-winning pitch.
  • Rapid Fire Round – pitch your concept to a panel of industry leaders and peers, putting your idea and pitching skills to the test.
  • Mentoring – receive tailored mentorship from industry experts who will help you bring your MedTech, BioTech or HealthTech innovation to market.
  • Access to the MedTech Actuator knowledge hub – commercialisation 101 curated content for researchers and medical professionals turned entrepreneurs.
  • Sprint Intensive – access a 3-day sprint intensive where you’ll dive into the world of entrepreneurship and commercialisation, including workshops, founder stories, panel discussions, activities, and heaps more!
  • Pitch Competition – bring together all your ideas in a short, 3-minute pitch to a select panel of judges to earn one of three places at the MedTech Actuator Showcase, a $15k cash prize and over $5k worth of in-kind prizes.
  • MedTech Actuator Showcase – pitch your idea to the ecosystem at the MedTech Actuator Showcase, a black-tie gala event for investors, industry-leaders, corporate partners and global MedTech companies.

The Origin winner will take home $15k in cash and have the opportunity to be fast-tracked through the application process for the MedTech Actuator – Asia Pacific’s MedTech accelerator – moving your product even closer to market.

Meet Amy Yu – MedTech Actuator Origin alumna

Photo of Amy Yu in MedTech Actuator superhero tee, Melbourne lane way by night.
Amy Yu, MedTech Actuator Origin alumna & Ventora Medical CTO.

“Ventora Medical spun out of the BioDesign Innovation program at the University of Melbourne. As soon as we graduated in 2018, we entered MedTech Actuator Origin. For Ventora, MedTech Actuator Origin really was the first point of validation from the MedTech entrepreneurial community in Melbourne. We were lucky enough to get through each round and be selected as a top five finalist.

You don’t know what you don’t know, and MedTech Actuator Origin taught us just that. At the bootcamps we took that all in, like sponges, and learnt so much from MedTech Actuator. This was backed up by networking with people who helped us achieve all of those unknowns and hit milestones.”

– Amy Yu, MedTech Actuator Origin alumna and Ventora Medical CTO, Forbes 30 Under 30

Key dates

  • Applications open: 6 Aug – 30 Sep
  • Finalists announced: 1 Oct
  • Online MedTech Actuator Origin Workshops: 7 Oct
  • Rapid Fire Round Pitch: 21 Oct
  • Mentoring and Sprint Intensive preparation: 22 Oct – 15 Nov
  • Sprint Intensive: 15 Nov – 17 Nov
  • Semi-finals Pitch: 17 Nov
  • MedTech Actuator Showcase and Finals Pitch: 9 Dec

Apply now

Are you ready to transform your idea and build your origin story – or do you know someone who is? Find out more about MedTech Actuator Origin and apply today.

Meet Gobind – Project Officer

Last year the MedTech ActuatorTM opened a second office – in Singapore. As part of our expansion through Asia Pacific, Project Officer Gobind Singh is supporting the work of Singapore-based founders to improve and save lives with health innovation.

As Project Officer Gobind helps to surround startups with the ecosystem support they need to bring their MedTech, HealthTech or BioTech innovation to the patients and clinicians who need it most.

With a focus on program delivery of the MedTech Actuator – Asia Pacific’s MedTech accelerator – Gobind connects startups with intensive mentorship, industry collaboration and capital raising support to help achieve in 15 months what can typically take 3 years or more.

“My role is where the MedTech Actuator’s rubber hits the road,” says Gobind. “I handle logistics, operations, communications, bookings and planning the program.”

Once the program begins, Gobind is the first point of contact for startups in Singapore. “I consult on their pitching, decks, IMs, strategy, and anything else they throw at me.”

Before joining the MedTech Actuator, Gobind was a fellow at the RMIT Health Transformation Lab where he broke down complex problems, generated new insights, and fostered new communities to help address the thorniest questions of health system reform, transformation, technology, and value.

In his role with the MedTech Actuator, Gobind is inspired by the success that startups can experience as a result of the program – and the human impact that having the right support can lead to.

“Watching startups succeed after taking feedback on board really inspires me,” says Gobind. “It makes me feel like I have contributed to the growth or commercialisation of the startups, which will in turn save human lives or make their recovery faster.”

Gobind has observed a common challenge experienced by MedTech startups in the process of commercialisation, with founders losing sight of the initial reasons that they began their trek down the entrepreneurial path.

“It is important to clarify, renew or even rework those initial aspirations as it will make the journey less bumpy – and the MedTech Actuator can help,” says Gobind.

“I am incredibly excited about the MedTech Actuator program’s growth to become the go-to MedTech accelerator in Asia Pacific.”

Find out more about MedTech Actuator – Asia Pacific’s MedTech accelerator.

NanoMSlide manufacturing smart microscope slides in Melbourne.

A new facility at the Australian National Fabrication Facility has made it possible for MedTech Actuator startup NanoMSlide to manufacture their smart nanotechnology microscope slides onshore for instant, more accurate cancer diagnosis.

Until now NanoMSlide has relied on overseas facilities for production of their invention. Housed at the Melbourne Centre for Nanofabrication Facility the new half-a-million dollar Phabler facility will enable industry, academia, and companies such as NanoMSlide to scale up production of nanoscale devices.

“With the Phabler facility we are now able to manufacture our slides right here in Melbourne and in quantities that will allow us to realise the full potential of our invention,” says NanoMSlide founder Professor Brian Abbey.

Current diagnostics of cancer in cells and tissues rely on chemicals, dyes, and extensive pre-processing of samples – taking valuable time and making accurate diagnosis more challenging. The new Phabler facility will make it possible for NanoMSlide to apply their patented nanopatterned coating to a conventional microscope slide, and create high-contrast images that instantly show the difference between cancerous and healthy cells.

NanoMSlide joined the MedTech Actuator in 2019 to develop their business model, connect with local and international partners and investors, build skills required to form a successful startup, and test their value proposition. The 15-month, industry-led, venture-backed program aggressively funds and accelerates medical, health and biological technology startups.

“One of the biggest challenges I faced in the MedTech Actuator was moving outside my comfort zone as a researcher,” says Brian. “As a startup founder you need to fulfil many roles and at the beginning I found pitching particularly hard. But as the program progressed I gained in confidence and experience.”

Brian is driven by the desire to improve outcomes for patients and to reduce the rate of misdiagnosis. Their invention is initially being used to diagnose early-stage breast cancer – and the team intend to scale for instant, more accurate diagnosis of other forms of cancer.

“As we are working on critical, life-changing problems, we constantly strive to develop our technology and deliver the best possible product,” says Brian.

The Medtech Actuator has connected the company with potential investors and industry partners. This dense innovation ecosystem is critical to success – Brian says it is important for MedTech entrepreneurs to seek advice from diverse experts and to be prepared to challenge your assumptions.

“We realised a few times in the MedTech Actuator that our initial plan was not ideal from a commercial perspective. While it was a difficult decision to change direction, the company is now in a much stronger position,” says Brian.

“I would recommend the MedTech Actuator to anyone with a great idea or potential product in the MedTech space – the community and support are fantastic and we had an unforgettable experience.”

Learn more about how the new Phabler tool is supporting NanoMSlide to manufacture their invention onshore and scale in this story from the Australian National Fabrication Facility.

La Trobe University aims to engage with industry partners and commercialise the NanoMSlide through a new spin-out company, AlleSense. Find out more.

Safeguarding frontline & essential workers from COVID-19 & future pandemics.

Expression of interest recently opened to invest in Soterius. The MedTech Actuator startup is scaling its COVID-19 biosensor to help protect workers and the wider community from devastating health, social and economic impacts of future pandemics.

The reliable, accurate and non-invasive Soterius biosensor delivers immediate results, informing whether an individual is required to test for infection and self-isolate or providing the all-clear to enter their work environment. The biosensor will initially be delivered to hospitals, with future applications in other frontline and essential worker settings including quarantine hotels, airports, and schools.

Emerging environmental viral sensors are bulky, energy intensive and specific to one virus. In contrast, the Soterius biosensor is so small that it fits on a personal fob card and is now scaling to detect other respiratory illnesses. Importantly, the biosensor is easy to use: individuals just swipe their card over a reader at checkpoints.

Prototype tests revealed that the biosensor detects SARS-CoV-2 spike protein in the picomolar range with impressive accuracy and reliability. SARS-CoV-2 is the virus responsible for COVID-19. This indicates that Soterius could be a top performing diagnostic for respiratory illnesses by immediately detecting the lowest presence of viral load.

Founded by Dr Alasdair Wood and Dr Chih Wei Teng, the Soterius biosensor is being developed in collaboration with the Burnet Institute, RMIT University, D+I and Vestech.

“In 2019, when the terms ‘social distancing’ and ‘stage 4 lockdown restrictions’ were unheard of, we observed inherent weaknesses in the world’s ability to protect itself against respiratory infection,” recalls Alasdair.

Alasdair and Chih Wei joined the MedTech Actuator – Asia Pacific’s MedTech catalyst – in 2019 to validate their ideas, connect with product designers and partners, and build the skills necessary for scaling their company.

“The MedTech Actuator is a complete package. You’re bound to learn and gain new perspectives, no matter how experienced you are,” says Chih Wei.

For Alasdair, the camaraderie and friendship amongst startups has also been a highlight.

“Peer learning is always great – we went through highs and lows together in a safe environment. I also love the people that populate the MedTech Actuator. The team is great and the people they bring in are amazing – including mentor Dr Elane Zelcer. Our new connections with peers, mentors and the wider ecosystem persist beyond the program,” says Alasdair.

“The MedTech Actuator provides the tools and connections to make ideas a reality, which is a very exciting proposition. But be ready to sprint!”

Reach out to Co-Founder and CEO Chih Wei Teng at chih(@)soterius.com.au to express interest in becoming a Soterius investor.

See the Soterius biosensor in this recent Channel 9 News story and read more about the technology and collaboration in this RMIT University media release.

Photo courtesy of RMIT University: Soterius sensors being prepared at RMIT University’s Micro Nano Research Facility for advanced manufacturing of cutting-edge electronics.

Asia Pacific’s best emerging health entrepreneurs join MedTech Actuator.

Entrepreneurs working to improve and save lives through health innovation have joined the MedTech Actuator – Asia Pacific’s MedTech catalyst.

We wish a warm welcome to our new cohort of clinicians, researchers and other changemakers with big plans to radically accelerate their medical, health or biological technology prototype or proof-of-concept:

  • GenEmbryomics: IVF Embryo Whole Genome Sequencing.
  • Gild: Improving healthcare access by developing gap-payment technology.
  • HatiSens: A handheld sensing device that can accurately diagnose heart attack in under 10 minutes.
  • Moon technologies: Providing emergency patients’ health data to paramedics in real-time.
  • Osteo-X: An internally self-locking intramedullary nail (orthopaedics) that reduces surgical time and radiation exposure.
  • Quitta: Developing safe, effective nicotine replacement therapies for the world’s 1.3 billion smokers.
  • The Mindful Mum (Rebranding to “Nourri”): A digital health platform that helps modern families nurture their health and happiness – for everyone’s benefit.
  • Virtetic: Empowering the prosthetics community through virtual reality.
  • XLR8: Developing wearable sensors and Rebee application to allow patients to perform physical rehabilitation exercises anywhere, any time.
  • Yabi: An innovative, accurate and automated method for monitoring and escalating surgical drain output.

The MedTech Actuator’s specialised acceleration model will surround the startups with the ecosystem support they need to bring their MedTech, HealthTech or BioTech innovation to the patients and clinicians who need it most.

Through MedTech Actuator’s intensive mentorship, industry collaboration, up to AUD$200K initial capital injection and capital raising support, the founders can achieve in 15 months what can typically take 3 years or more.

Embedded in the MedTech Actuator™ ecosystem, they will radically advance their technology development, raise seed capital, and build critical business and management skills. They will become primed and ready to grow their venture even further – including raising series A funding, commencing clinical trials, gaining regulatory approvals, and moving to at-scale manufacturing, and market launch.

Integrated across Asia Pacific, the industry-led MedTech Actuator will open an unrivalled network to founders, including 85 partners and 75 mentors from some of the largest names in health innovation spanning multi-national corporations, hospitals and clinicians, investor groups and VCs, professional service partners, universities and research institutions, and product development firms.

They will go on to join an alumni network of the brightest emerging startups from across Asia Pacific and our networks are their networks as they scale up, prepare for exit and beyond.

To follow founders and their journey sign up to our newsletter below and connect with us on LinkedIn and Twitter.

Meet Maria – Head of Programs

With a career that spans the US, Australia, Belgium, and Russia – managing international activities for over 200 startups – MedTech Actuator Head of Programs Maria Pelipas is supporting Asia Pacific’s next wave of health entrepreneurs to improve and save lives.

A seasoned program manager, Maria has experience in BioTech strategy consulting, partnerships, accelerators, investment funds, a startup, and innovation agencies. She holds a Master of International Relations from Tomsk State University, Russia and a Master of European Studies from the University of Brussels, Belgium – and is qualified in project management, venture deals and tech transfer management.

“My role involves managing the flagship MedTech Actuator – Asia Pacific’s MedTech accelerator,” says Maria. “We help founders to achieve in 15 months what usually takes three years or more – the program is unusually long for an accelerator due to the complexity of the medical space.”

Maria explains that bringing a MedTech, HealthTech or BioTech innovation to market requires an industry-specific acceleration model. As a life sciences startup, they are likely to design and manufacture a physical product, navigate clinical trials, regulatory submissions, reimbursement models and multiple customer and stakeholder groups.

“It definitely brings a lot of exciting challenges which we tackle as a team and with our dense ecosystem of partners,” says Maria.

Maria has enjoyed supporting teams through diverse challenges including founders moving at a different pace across verticals such as medical devices and digital health, and founders with research backgrounds taking the first steps to nurture their idea into a solid business.

“What excites me the most is seeing the growth in real-time,” says Maria. “I would even compare it to being a passenger in the backseat of a fast moving car – you help startups accelerate by fine-tuning the course. It is pure enjoyment to plant those seeds and watch the growth unfold.”

Maria has recently onboarded a new cohort of Asia Pacific’s best MedTech and HealthTech entrepreneurs and will kick off the program in the weeks ahead. Maria anticipates a dynamic journey for the startups that span Australia and Singapore and looks forward to lots of in-person glitz and glamour for all startups.

Maria is blown away by the MedTech Actuator team, saying that it is a kind and welcoming environment where people with different backgrounds and experiences come together to drive health innovation forward.

“Running this program reminds me of building a startup – we come up with MVP ideas; choose the best solution; pivot when we face obstacles; and keep building the best experience for our startups,” says Maria.

“I am impressed with how far the MedTech Actuator team has come since the program’s inception in 2018 and look forward to taking this to the next level, applying all of my skills, knowledge, and passion.”